Palmoplantar Pustulosis and Acrodermatitis in a Patient Treated With Infliximab for Crohn's Sacroiliitis

Wermuth, Jürg; Kind, Fabiola; Steuerwald, Michael

doi:10.1016/j.cgh.2008.08.009

Cited by 11 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our present study and recent reports in the literature by others have identified a span of cutaneous eruptions in patients undergoing anti‐TNF therapy, ranging from infusion and injection site reactions to dermatological eruptions including psoriasis and psoriasiform dermatitis, eczematous‐dermatitis, lupus erythematosus, vasculitis, lichenoid reactions, granulomatous eruptions, infections and neoplastic eruptions (including cutaneous lymphoma, non‐melanoma skin cancer and melanoma), (Table 2). 2–45 Of these, the greatest strength of association is noted between anti‐TNF agents and eruptions of the psoriasiform, lupus‐like, vasculitic and infectious varieties 46 . To our knowledge, our cases of Sweet's‐like hypersensitivity and neutrophilic eccrine hidradenitis are the first reported in association with anti‐TNF‐alpha agents.…”

Section: Discussionmentioning

confidence: 84%

Broad range of adverse cutaneous eruptions in patients on TNF‐alpha antagonists

et al. 2012

View full text Add to dashboard Cite

Biologic therapies targeting tumor necrosis factor (TNF)-alpha have become a mainstay in the management of a number of autoimmune diseases. We report a series of adverse skin eruptions in six patients (four females, two males, age: 21-58 years, mean: 39) receiving 4 months to 10 years (mean 3.1 years) of anti-TNF-alpha therapies (infliximab, n = 4; adalimumab, n = 1 or etanercept, n = 1). The following drug-associated diagnoses were made in eight skin biopsies performed at Massachusetts General Hospital between 3/2007 and 10/2010: pustular folliculitis, psoriasis, interface dermatitis, neutrophilic eccrine hidradenitis, Sweet's syndrome, lupus, vasculitis and palmoplantar pustulosis. The descriptions of neutrophilic eccrine hidradenitis-like and Sweet's-like hypersensitivity eruptions induced by anti-TNF-alpha therapies are the first such cases described in the literature. Each cutaneous eruption improved or resolved with switching to a different TNF-alpha inhibitor, discontinuation of the anti-TNF-alpha agent, and/or topical or systemic steroids. There was a clear chronologic relationship with, and clinical remission upon withdrawal or steroid suppression of the anti-TNF-alpha agents. The mechanism for such diverse cutaneous eruptions among this class of medications remains poorly understood. The cutaneous adverse reaction profile of TNF-alpha inhibitors is broad and should be considered in the histopathologic differential in this clinical setting.

show abstract

Section: Discussionmentioning

confidence: 84%

Broad range of adverse cutaneous eruptions in patients on TNF‐alpha antagonists

et al. 2012

View full text Add to dashboard Cite

show abstract

“…A summary of demographics of the 155 patients with biologic‐associated PPP and PPPP are shown in Table 1 8,11,12,14–63 . Overall, the mean age was 44.1 (range: 22–79), with a female preponderance (71.6%, n = 53, not reported [NR, n = 81]), which was similar between patients with biologic‐associated PPP and PPPP (42.3 years and 69% female vs. 45 years and 73.3% female, respectively).…”

Section: Resultsmentioning

confidence: 98%

“…After the removal of duplicates, 377 articles were screened and 172 were excluded, leading to 205 full‐text articles accessed for eligibility. A total of 53 articles met inclusion criteria for this qualitative synthesis 8,11,12,14–63 …”

Section: Resultsmentioning

confidence: 99%

Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review

Mufti

Zaaroura

et al. 2022

Int J Dermatology

View full text Add to dashboard Cite

Background Palmoplantar pustulosis (PPP) and palmoplantar pustular psoriasis (PPPP) are chronic inflammatory skin conditions characterized by eruptions of sterile pustules on the palms and/or soles. Biologic use has been associated with PPP and PPPP development in the literature.Objectives To identify PPP and PPPP associated with biologics and summarize reported treatments and outcomes.Methods We systematically searched in MEDLINE and Embase for articles that reported PPP or PPPP during biologic treatment. After a full-text review, 53 studies were included for analysis. ResultsWe identified 155 patients with PPP/PPPP onset during biologic treatment, with a mean age of 44.1 years and a female preponderance (71.6%). The most frequently reported biologics were adalimumab (43.9%) and infliximab (33.3%). IL-17 inhibitors, secukinumab (7.6%) and brodalumab (1.5%), were reported only in association with PPPP.Overall, 58.8% of patients had complete remission (CR) in 3.6 months and 23.5% had partial remission (PR) in 3.7 months. The most common treatments that led to CR were topical corticosteroids (n = 16) and biologic switching (n = 8).Conclusions Clinicians should anticipate PPP or PPPP as potential drug reactions to biologics such as adalimumab and infliximab. Large-scale studies are required to confirm our findings and further explore the pathogenesis for biologic-associated PPP and PPPP.

show abstract

“…In addition to psoriasis treatment, anti-TNF-α Mabs have been used for treatment of other immune-mediated inflammatory diseases including rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, and ulcerative colitis [ 14 ]. Conversely, use of anti-TNF-α Mabs can lead to serious adverse side effects, other malignant diseases [ 15 , 16 ] autoimmune diseases [ 17 , 18 ] and development of skin lesions or psoriasis [ 19 , 20 ]. Moreover, a sub-set of patients do not respond to anti-TNF-α therapies or alternatively develop resistant after initial improvement [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of Anti-TNF-α Activities in Keratinocytes Expressing Inducible TNF- α: A Novel Tool for Anti-TNF-α Drug Screening

et al. 2016

View full text Add to dashboard Cite

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine important in normal and pathological biological processes. Newly synthesized pro-TNF-α is expressed on the plasma membrane and cleaved to release soluble TNF-α protein: both are biologically active. Secreted TNF-α signals through TNF receptors and the membrane-bound TNF-α acts by cell contact-dependent signaling. Anti-TNF-α antibodies have been used effectively for treatment of chronic inflammation, however with adverse side effects. Thus, there is a need for new anti-TNF-α small molecule compounds. Anti-TNF-α activity assays involve treatment of keratinocytes with exogenous TNF-α before or after anti-TNF-α incubation. However, this model fails to address the dual signaling of TNF-α. Here we describe a Doxycycline (Dox)-inducible TNF-α (HaCaT-TNF-α) expression system in keratinocytes. Using this in-vitro model, we show cell inhibition and induced expression of pro-inflammatory cytokines and markers, including IL-1β, IL-6, IL-8, NF-κB1, and KRT-16, similar to cells treated with exogenous TNF-α. Sufficient secreted TNF-α produced also activated IL-1β and IL-8 expression in wt HaCaT cells. Importantly, stimulated expression of IL-1β and IL-8 in HaCaT-TNF-α were blocked by Quercetin, a flavanol shown to possess anti-TNF-α activities. This novel in vitro cell model provides an efficient tool to investigate the dual signaling of TNF-α. Importantly, this model provides an effective, fast, and simple screening for compounds with anti-TNF-α activities for chronic inflammatory disease therapies.

show abstract

Palmoplantar Pustulosis and Acrodermatitis in a Patient Treated With Infliximab for Crohn's Sacroiliitis

Cited by 11 publications

References 1 publication

Broad range of adverse cutaneous eruptions in patients on TNF‐alpha antagonists

Broad range of adverse cutaneous eruptions in patients on TNF‐alpha antagonists

Biologic therapies associated with development of palmoplantar pustulosis and palmoplantar pustular psoriasis: a systematic review

Assessment of Anti-TNF-α Activities in Keratinocytes Expressing Inducible TNF- α: A Novel Tool for Anti-TNF-α Drug Screening

Contact Info

Product

Resources

About